"Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis". In this study led by the Tschumperlin lab, Haak et al. has identified a therapeutic approach for inhibiting YAP/TAZ specifically in fibroblasts by agonizing the dopamine receptor D1 (DRD1). DRD1 agonists inhibited YAP/TAZ and had therapeutic effects in mouse models of lung and liver fibrosis. Our lab has contributed with experiments studing the role of YAP/TAZ in the development of lung fibrosis in preclinical models.